Search Results

1-8 of 8 results for primarymember:"Pauline Latham"

Show detailed: On Off

Results: 10 20 50 100

Sort by: Newest first Oldest first

To ask the Secretary of State for Health what steps his Department plans to take in respect of strategic health authorities (SHAs) which have exhausted their allocation of the Cancer Drugs Fund; and what will happen to the Cancer Drugs Fund budget of SHAs which do not spend their total...

Asked by

Pauline Latham (Conservative)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

27 February 2012

Reference

95661; 541 c107W

House

House of Commons

Melanoma

Westminster Hall adjournment debate on the treatment of melanoma and availability of the drug ipilimumab.

Lead member

Pauline Latham

Answering member

Paul Burstow

Department

Department of Health

Type

Adjournment debates

Date

18 January 2012

Reference

538 c320-6WH

House

House of Commons

Skin Cancer

(2) what recent assessment he has made of the adequacy of provision of clinical nurse specialists for metastatic melanoma; and if he will make a statement;

Asked by

Pauline Latham (Conservative)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

21 November 2011

For answer on

23 November 2011

Answered on

25 November 2011

““Improving Outcomes: A Strategy for Cancer””, published on 12 January, made the collection of data on secondary breast cancer a priority for 2011. Pilot projects are already under way and we anticipate that routine collection will begin in April 2012. It is our intention that the learning from this exercise will be applied to the collection of information on other forms of metastatic cancer in the future. No decisions regarding the next steps for metastatic data collection have been made at this time and are unlikely to be made until the routine collection of secondary-breast cancer data has been properly established and quality assured.The ““2010 Census of Cancer Specialist Nurses (CNSs) in England”” reported that there were 2,164.2 whole time equivalents CNSs in the 28 English cancer networks of which 119.68 worked in skin cancer and in the 2010 Cancer Patient Experience Survey 75% of skin cancer patients reported having a CNS.The survey also showed that cancer patients who have support from a CNS have an overall better experience of care. We expect the national health service to consider this in developing their policies to improve patient experience. To support the NHS to develop the CNS work force, the strategy sets out our intention to build the evidence base for the benefits and-costs savings that CNSs can offer. This follows an independent report we published in December 2010 that showed that, in many scenarios, the costs of additional support roles are likely to be outweighed by the savings that can be achieved.Data concerning the number of elective and emergency admissions for patients with a diagnosis of skin cancer or metastatic melanoma in the latest year for which figures are available by primary care trust have been placed in the Library. These data should not be described as a count of people as the same person may have been admitted on more than one occasion. To protect patient confidentiality figures between one and five have been replaced with an asterisk, and where it was still possible to identify numbers from the total the next smallest has been replaced.

Date

25 November 2011

Reference

82637; 536 c631W

House

House of Commons

Skin Cancer

To ask the Secretary of State for Health (1) whether, following the pilot of the collection of data on metastatic breast cancer, he plans to collect data on metastatic melanoma;

Asked by

Pauline Latham (Conservative)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

21 November 2011

For answer on

23 November 2011

Answered on

25 November 2011

Date

25 November 2011

Reference

82613; 536 c631W

House

House of Commons

Skin Cancer

(3) how many (a) elective and (b) emergency admissions were recorded for patients with a diagnosis of (i) skin cancer and (ii) metastatic melanoma by primary care trust in the latest year for which figures are available.

Asked by

Pauline Latham (Conservative)

Answering body

Department of Health

Type

Written questions

Status

Answered

Tabled on

21 November 2011

For answer on

23 November 2011

Answered on

25 November 2011

Date

25 November 2011

Reference

82639; 536 c631W

House

House of Commons

Melanoma: Drugs

To ask the Secretary of State for Health if he will request the National Institute for Health and Clinical Excellence to reconsider its recent decision not to recommend the use of Yervoy for patients with advanced melanoma; and if he will take steps to make provisions for the use of...

Asked by

Pauline Latham (Conservative)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

25 October 2011

Reference

76556; 534 c199W

House

House of Commons

Colorectal Cancer: East Midlands

To ask the Secretary of State for Health whether the East Midlands Cancer Drugs Fund provides funding for Avastin for (a) first-line treatment for bowel cancer and (b) second-line treatment.

Asked by

Pauline Latham (Conservative)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

18 July 2011

Reference

66204; 531 c632W

House

House of Commons

Skin Cancer

To ask the Secretary of State for Health what steps his Department is taking to reduce the incidence of and mortality rates from malignant melanoma.

Asked by

Pauline Latham (Conservative)

Answering body

Department of Health

Type

Written questions

Status

Answered

Date

13 December 2010

Reference

29544; 520 c620W

House

House of Commons

Librarians' tools

Type

House

Session

Year

Department

Member

Primary member

Answering member

Legislative stage

Legislation

Subject

Publisher